key: cord-0037381-w3larngb authors: Yanik, Gregory A.; Cooke, Kenneth R.; Ho, Vincent T.; Richardson, Paul G. title: Pulmonary and Hepatic Complications of Hematopoietic Cell Transplantation date: 2013-10-15 journal: Hematopoietic Cell Transplantation in Children with Cancer DOI: 10.1007/978-3-642-39920-6_5 sha: 17c810bd508575557dc2638b14d222805dae4239 doc_id: 37381 cord_uid: w3larngb Significant advances have been made in allogeneic transplantation for both adults and pediatric transplant recipients over the past 20 years, corresponding with dramatic declines in treatment-related mortality (TRM). The cumulative incidence of TRM at 1 year following unrelated donor transplants has decreased from 40 to 15 % between 1987 and 2006 for children with acute leukemia, the primary indication for transplant in the pediatric population (MacMillan et al., Biol Blood Marrow Transpl 14(9 Suppl):16–22, 2008). Improvements in conditioning regimen, supportive care, and human leukocyte antigen (HLA) testing have all been associated with incremental improvements in survival during this period. In particular, the management of both infectious and noninfectious organ complications has changed dramatically, with improved sensitivity for diagnostic testing for pathogens and tremendous improvements in our understanding of organ complications. Two organ complications in particular, pulmonary and hepatic, have been a major focus of investigation over the past several decades. The introduction of tumor necrosis factor (TNF) inhibitors for the management of acute, noninfectious lung injury and the introduction of an endothelial stabilizing agent (defibrotide) for the management of hepatic veno-occlusive disease have been major advances in the past decade. Signifi cant advances have been made in allogeneic transplantation for both adult and pediatric transplant recipients over the past 20 years, corresponding with dramatic declines in treatment-related mortality (TRM). The cumulative incidence of TRM at 1 year following unrelated donor transplants has decreased from 40 to 15 % between 1987 and 2006 for children with acute leukemia, the primary indication for transplant in the pediatric population (MacMillan et al. 2008 ) . Improvements in conditioning regimen, supportive care, and human leukocyte antigen (HLA) testing have all been associated with incremental improvements in survival during this period. In particular, the management of both infectious and noninfectious organ complications has changed dramatically, with improved sensitivity for diagnostic testing for pathogens and tremendous improvements in our understanding of organ complications. Two organ complications in particular, pulmonary and hepatic, have been a major focus of investigation over the past several decades. The introduction of tumor necrosis factor (TNF) inhibitors for the management of acute, noninfectious lung injury and the introduction of an endothelial stabilizing agent (defi brotide) for the management of hepatic veno-occlusive disease have been major advances in the fi eld. Pulmonary toxicity, both infectious and noninfectious, develops in 25-50 % of hematopoietic cell transplant (HCT) recipients, accounting for nearly 50 % of all transplant-related deaths (Clark et al. 1999 ; Crawford and Hackman 1993 ; Weiner et al. 1986 ; Quabeck 1994 ; Kantrow et al. 1997 ; Afessa et al. 2001 ) . Despite advances in treating opportunistic organisms, infectious lung injury remains a signifi cant problem, particularly in patients with graft-versus-host disease (GVHD) or in individuals with delayed immune reconstitution. On the other hand, noninfectious lung injury can be either acute or chronic depending upon the time of occurrence posttransplant and the rate of disease progression. Acute lung injury may be alloreactive or non-alloimmune, secondary to cardiogenic shock or chemoradiotherapy effects. Chronic lung injury may be obstructive or restrictive in nature, depending upon the pathogenesis of the lung injury pattern (Holland et al. 1988 ; Schultz et al. 1994 ; Crawford et al. 1995 ; Sullivan et al. 1992 ; Sanchez et al. 1997 ; Badier et al. 1993 ; Quigley et al. 1994 ) . This section will review the defi nitions, risk factors, and pathogenesis of lung injury occurring after HCT. Because respiratory distress can progress rapidly once established, the timely coordination of care between the hematology-oncology, pulmonary, and often intensivist teams is essential to optimizing outcomes. Determination of the severity of respiratory dysfunction, including an assessment of the need for supplemental oxygen support, overall fl uid balance, renal function, and cardiac output should be followed by radiographic imaging. In general, an initial chest x-ray or CT scan will identify the presence of lobar, multilobar, or diffuse pulmonary infi ltrates ( Fig. 5.1 ). While such fi ndings may impact the decision-making process, they are nondiagnostic in and of themselves. In the absence of obvious cardiac failure or iatrogenic fl uid overload, bronchoscopy with bronchoalveolar lavage (BAL) should be considered when infi ltrates are present. BAL samples should be sent for a number of diagnostic tests to determine the potential presence of community or hospital acquired and opportunistic infections. Besides bacterial, fungal, and cytological stains, quantitative cultures should be performed on BAL fl uid for diagnostic purposes. In addition, direct fl uorescent antibody stains, centrifugation cultures (shell vial), or polymerase chain reaction (PCR) assays may also be very useful in isolating/identifying various viral pathogens. The role of BAL in HCT recipients remains a matter of debate, with the diagnostic yield ranging from 31 to 67 % in various reports (Huaringa et al. 2000 ) . In many cases, patients are referred for BAL after several days of symptoms and only after empiric antibiotic therapy has been well established. Empiric antibiotic management has been reported to provide inadequate coverage in over 40 % of patients with pathogens identifi ed on subsequent BAL (Ascioglu et al. 2002 ; Prasoon et al. 2004 ). Furthermore, prolonged empiric antibiotics may diminish growth of potential pathogens, limiting the subsequent utility of bronchoscopic procedures. In a retrospective study of 598 patients who underwent BAL within the fi rst 100 days post-HCT at MD Anderson Cancer Center, the overall yield of BAL was 55 %, with the yield 2.5 times greater among patients in whom a BAL was performed within the initial 4 days of clinical presentation. In addition, pneumonia-associated deaths were three times higher (18 % vs. 6 %) in those patients undergoing late bronchoscopy, following 4 days of clinical symptoms (Shannon et al. 2010 ). Yanik and colleagues examined 444 bronchoscopy procedures completed on 300 patients who received HCT at the University of Michigan from 2001 to 2007 (Yanik et al. 2008a ) . Only 13 % of BAL specimens collected in the fi rst 30 days of HCT were positive for infection, with the diagnostic yield increasing to 33 % between days 31 and 100. Hence, while the majority of HCT patients requiring BAL within the fi rst 100 days may be categorized as having idiopathic pneumonia syndrome (IPS), a signifi cant number of individuals will have evi-dence for infection. BAL resulted in changes in medical management in approximately 60 % of cases. Factors contributing to infectious pneumonitis following HCT may include suppression of laryngeal or cough refl exes, impaired removal of respiratory secretions due to decreased mucociliary clearance or airway obstruction, and impaired humoral and cellular defense mechanisms. Quantitative and/or qualitative defects in neutrophil or lymphoid function allow nonpathogenic organisms to ultimately become both invasive and pathogenic. With the lungs of a 10 kg child exposed to approximately 2,000 liters of inhaled air every 24 hours, the number of organic and inorganic particles and potential pathogenic organisms processed by our respiratory tract each day is countless. A fi ne balance exists between those organisms that become true pathogens and those that remain commensurate and often depends upon the quantity of inoculum received and host-defense factors outlined above. Infectious pneumonitis may be subdivided into those associated with either interstitial or parenchymal involvement. Common pathogens that cause interstitial pneumonitis include community-acquired respiratory viruses (e.g., parainfl uenza, respiratory syncytial virus (RSV), infl uenza, metapneumonia), mycoplasma, and opportunistic pathogens such as Pneumocystis jiroveci (PCP), whereas bacterial and fungal pathogens are more frequently associated with parenchymal changes. CMV pneumonitis remains a signifi cant cause of morbidity and mortality following allogeneic HCT. In the absence of a CMV prevention strategy (e.g., preemptive monitoring of CMV by plasma PCR for antigenemia or universal prophylaxis), CMV pneumonitis may develop during the fi rst 100 days following HCT with a peak incidence at approximately 8 weeks. In the current era, most CMV infections occur after the monitoring or prophylaxis period ends. CMV pneumonitis in patients with chronic GVHD has also been well documented (Boeckh and Ljungman 2002 ; Osarogiagbon et al. 2000 ) . With the availability of improved antiviral therapy, the mortality rate associated with CMV pneumonitis has declined signifi cantly in recent years (Reusser 1991 ) . Risk factors for the development of CMV disease include the presence of acute GVHD, recipient CMV seropositivity, transplantation for a hematologic malignancy, and the use of antithymocyte globulin during the transplant process (Osarogiagbon et al. 2000 ; Ljungman et al. 2003 ) . Radiological manifestations of CMV range from diffuse interstitial opacities to widespread air space consolidation (Shimada et al. 2004 ) . Histopathology remains the gold standard for identifi cation of CMV pulmonary disease. Though molecular techniques have an excellent sensitivity for detection of infection, they may be less specifi c in regards to identifying CMV pneumonitis. The potential for polymicrobial superinfections is another concern in the transplant patient with CMV pulmonary disease, given the multiple issues often involved in patients with active CMV infections, including the concurrent use of systemic corticosteroids and prolonged empiric antibiotic usage. Respiratory syncytial virus (RSV) is a singlestranded, enveloped RNA virus that presents as a self-limiting upper respiratory tract infection in immunocompetent individuals or a potentially fatal pneumonitis in immunocompromised patients (Ebbert and Limper 2005 ) . Outbreaks in patients undergoing allogeneic HCT have been associated with mortality rates as high as 78 % (Englund et al. 1988 ; Harrington et al. 1992 ). In the United States, the onset of RSV infections typically begins in November and continues for approximately 24 weeks. The organism is highly contagious, with transmission occurring primarily through surfaces contaminated with viralladen nasal or oral secretions. Even in immunocompetent patients, native memory responses are incomplete, allowing for repeated infections. The overall virulence of this agent places the immunocompromised patient at particular risk for fatal lower respiratory tract infections during the seasonal period (Ebbert and Limper 2005 ) . Radiographically, patchy alveolar or diffuse interstitial infi ltrates may be seen. Clinically, affected patients may exhibit profound dyspnea and hypoxemia, with or without concurrent upper respiratory tract symptoms. Less than 50 % of patients with lower tract involvement have preceding or concurrent nasopharyngeal symptoms (Ebbert and Limper 2005 ; Harrington et al. 1992 ) . The use of aerosolized ribavirin (6 g/day) using small particle generators has resulted in a decrease in RSV shedding, but clinical effi cacy has not been proven (Ebbert and Limper 2005 ; Boeckh et al. 2007 ) . Palivizumab may be considered as prophylaxis option in adults with lower respiratory tract disease (Hynicka and Ensor 2012 ) . The clinical impact of recently described viruses including human metapneumovirus and non-SARS human coronaviruses is not yet clear. Human metapneumovirus (hMPV) is a paramyxovirus recently recognized as the fi rst human pathogen within the genus Metapneumovirus (van den Hoogen et al. 2004 ) . The virus was fi rst identifi ed in the Netherlands in 2001 and was recently reported as a potential pathogen in allogeneic transplant recipients (Englund et al. 2006 ). In the bone marrow transplant setting, infected patients typically present within the fi rst 50 days posttransplant and exhibit clinical and radiographic fi ndings similar in appearance to IPS. Rapid progression of respiratory symptoms may occur, with a median of 4 days reported between initiation of oxygen support and death (Englund et al. 2006 ) . The clinical spectrum of hMPV as a cause of interstitial pneumonia posttransplant remains ill defi ned, with issues such as the frequency of asymptomatic shedding, improved detection methods, and treatment strategies all under investigation. The reactivation of latent viruses, especially herpes family and adenovirus, may also clinically mimic interstitial pneumonitis (Shields et al. 1985 ) . However, in the vast majority of cases, clinical symptoms related to systemic involvement are manifested by signs of disease in other organs, including abdominal pain, elevation of serum hepatic transaminases with CMV, varicella zoster virus, or adenovirus, and oral mucosal involvement with herpes simplex viruses. Bacterial pneumonia typically presents as alveolar and parenchymal fi lling infi ltrates, with concurrent fever and clinical symptoms (chest pain, tachypnea, cough). Pneumonias due to bacteria are common in the pre-engraftment period, including infections from both Grampositive ( Staphylococcus and Streptococcus species) and a wide range of Gram-negative organisms. Factors that impact the risk of early bacterial pneumonia include oral-pharyngeal mucositis, focal or diffuse enteritis, aspiration risk due to the infl uence of opiates and sedatives, and catheter-related risks. Pneumonias due to Gram-negative organisms Pseudomonas aeruginosa , Klebsiella pneumonia , Acinetobacter , Escherichia coli , and Enterobacter have all been commonly reported within the fi rst 100 days posttransplant, of particular concern in patients with concurrent gastrointestinal GVHD (Martin-Pena et al. 2011 ) . Later onset bacterial pneumonias (following day 100 post-HCT) are not uncommon in patients with concurrent chronic GVHD, especially prominent in patients with bronchiolitis obliterans syndrome (BOS) or those on systemic corticosteroids for chronic GVHD management. Fungi are historically classifi ed as either yeasts ( Candida , Trichosporon , Cryptococcus ) or molds, with molds subdivided by septate hyphae ( Aspergillus , Scedosporium , Fusarium , Histoplasma , Penicillium ) or aseptate hyphae ( Mucor , Rhizopus ). Fungi rarely cause acute infections in the immunocompetent host. Candida species, for example, are commensal fl ora of the nasopharyngeal tract and skin, rarely causing lower respiratory tract invasion in the immunocompromised host. Candidal infections and candidemia are commonly seen when breakdowns in epithelial and mucosal barriers occur in conjunction with concurrent use of empiric antibacterial agents that eradicate normal bacterial fl ora. Tissue cultures are required to establish the diagnosis of invasive Candida , with both bronchoalveolar lavage and sputum cultures poor predictors of invasive pulmonary candidal infections. In contrast, invasive fungal infections from pathogenic molds are a common cause of pneumonia in the posttransplant setting, with invasive Aspergillus infections occurring in 10-15 % of allogeneic transplant recipients. Aspergillus pneumonia has been reported at a median 92 days posttransplant, and overall survival from invasive Aspergillus has been reported at less than 30 % (Grow et al. 2002 ) . Risk factors for the development of Aspergillus pneumonia include prolonged corticosteroid usage (≥1 mg/kg/day), history of recent cytomegalovirus (CMV) infection, and prolonged neutropenia (Grow et al. 2002 ; Garcia-Vidal et al. 2008 ) . The combination of neutropenia, impaired T-cell function, and abnormal glucose metabolism is an additive risk for invasive fungi. Defi nitions of invasive fungi were established in 2002 to distinguish colonization from actual infection. Invasive fungal infections are now classifi ed as proven, probable, or possible. Proven infections require histologic confi rmation or a positive tissue culture. Probable infections require both a host factor and clinical and/or fl uid cultures consistent with an invasive fungus (De Pauw et al. 2008 ) . Currently available tests for the serum fungal markers betaglucan and galactomannan could also be useful to differentiate colonization from invasive infections with Candida and aspergillus species, respectively. Radiographic features of invasive fungi are heterogenous, with small and large nodules, ground-glass opacifi cations, cavitary lesions, treein-bud appearance, and halo signs can be observed on chest radiograph or computed tomography (CT). Treatment of invasive fungi makes use of the unique biology of the organism. Fungi contain a cell membrane with ergosterol and a cell wall with beta-glucan, both targets for antifungal therapy. Voriconazole provides effective therapy for a wide range of pathogenic fungi, excluding Mucor species. Both posaconazole and lipid formulations of amphotericin B provide coverage for Mucor , in addition to coverage for Aspergillus and Candida species. The clinician initiating voriconazole or other antifungal "azole" therapy should be mindful of its impact on cytochrome p450-dependent drugs, including the calcineurin inhibitors tacrolimus and cyclosporine and the mTor inhibitor sirolimus. When voriconazole is initiated, doses of tacrolimus and cyclosporine should be reduced by 50 %, with even greater dosing reduction (90 %) for sirolimus if being given in conjunction with voriconazole. Noninfectious lung injury may be mediated by either alloimmune or non-alloimmune mechanisms. Common alloimmune lung complications post-HCT include IPS, transfusion-related lung injury (TRALI), diffuse alveolar hemorrhage (DAH), or peri-engraftment respiratory distress syndrome (PERDS), existing as a subset of IPS, with both DAH and PERDS existing as a subset of IPS. Non-alloimmune conditions may include the direct cytotoxic effects of conditioning therapy and cardiogenic causes of pulmonary edema. Initially described in the 1970s, chemotherapyassociated pulmonary toxicity has been reported in association with multiple chemotherapeutic busulfan agents, including BCNU, busulfan, cyclophosphamide, and melphalan. In particular, BCNUrelated lung injury is acute in onset and develops within the fi rst 3 months following HCT in 10-40 % of patients receiving this therapy (Aronin et al. 1980 ) . Clinically, BCNU-related lung injury is associated with a nonproductive cough with increasing dyspnea in the context of rapidly progressing, bilateral, interstitial infi ltrates on both chest radiographs and CT. Pulmonary function testing reveals a restrictive pattern of lung injury, with diminished forced vital capacity and total lung capacity noted (Lane et al. 2012 ) . The pathogenesis of BCNUrelated lung injury has been ill defi ned, though increased production of fi brogenic factors such as platelet-derived growth factor-β, insulin-like growth factor I, and transforming growth factor-β1 has been implicated (Shen et al. 2004 ) . Treatment with pulsed doses of corticosteroids early in the clinical course signifi cantly decreases the morbidity and mortality associated with this condition and is key for successful outcomes; if untreated or recognized late in its clinical course, severe pulmonary fi brosis may develop (Shen et al. 2004 ). Busulfan, either alone or in combination with other cytotoxic agents, has also been implicated in posttransplant lung dysfunction. However, the use of pharmacokinetic targeting of busulfan dosing has decreased the incidence of acute lung injury. Similar to BCNU administration, increased pulmonary toxicity has been noted in patients receiving prior mediastinal radiotherapy, following either autologous or allogeneic HCT (Bolling et al. 2009 ). TRALI is one of the leading causes of mortality following infusions of plasma-containing blood products, estimated to occur in 1:1,000 to 1:5,000 transfusions (Silliman et al. 2003 ; Kopko et al. 2002 ) . All plasma-containing blood products, including whole blood, packed red blood cells (PRBC), fresh frozen plasma (FFP), platelets, cryoprecipitate, granulocytes, immune globulin infusions, and stem cell products, have been linked with the development of TRALI, with albumin the sole exception (Swanson et al. 2006 ). The diagnosis is based upon clinical symptoms with acute onset of dyspnea and respiratory distress typically occurring 1-6 hours after transfusion. Chest radiographs reveal diffuse pulmonary infi ltrates refl ecting edema from increased pulmonary vascular permeability. Pathologically, neutrophil infi ltrates and overexpression of neutrophil-related cytokines and chemokines have been linked to its development. With mortality rates approximating 5-10 %, TRALI accounts for 47 % of all transfusion-related deaths. Treatment is generally supportive. Discontinuation of the blood product, corticosteroid administration, forced diuresis, and respiratory support results in recovery within 3-4 days in the majority of patients. In over 70 % of cases, donor antibodies directed against HLA class I or II epitopes on recipient hematopoietic cells have been identifi ed as the primary cause of the TRALI event, but in rare cases the antibody may be present in the recipient's plasma and may be directed against transfused donor leukocytes (Kopko et al. 2003 ; Kao et al. 2003 ) The use of high plasma volume blood products from alloimmunized donors, including apheresis stem cell products and platelets, is associated with high risk for the development of TRALI (Reesink et al. 2012 ) . IPS refers to an acute lung injury that occurs post-HCT, associated with diffuse alveolar damage in the absence of lower respiratory tract infection. In 1993, a National Institute of Health (NIH) workshop proposed a broad defi nition for IPS, the defi -nition recently updated by an American Thoracic Society research statement (Table 5 .1 ) (Clark et al. 1993 ). IPS encompasses a spectrum of disorders, including diffuse alveolar hemorrhage (DAH), peri-engraftment respiratory distress syndrome (PERDS), acute idiopathic interstitial pneumonitis, and chemotherapy-related lung injury. The diagnosis, however, is often one of exclusion, with infectious pneumonitis, sepsis syndrome, cardiac failure, and iatrogenic fl uid overload all potentially exhibiting similar clinical presentations. The cumulative incidence of IPS in the fi rst 120 days after allogeneic HCT ranges between 2 and 15 %, with a median onset 14-42 days post-HCT and mortality rates 50-80 % within 28 days of diagnosis (Panoskaltsis-Mortari et al. 2011 ; Fukuda et al. 2003 ; Sakaguchi et al. 2012 ; Yanik et al. 2008b ). IPS has been reported in 8.0 % of pediatric allogeneic transplants, with median onset at 67 days posttransplant (Sakaguchi et al. 2012 ). Long-term survival for affected children is poor, with TRM signifi cantly higher in affected than non-affected patients (5-year TRM: 52 % vs. 13 %, p = 0.001) (Sakaguchi et al. 2012 ) . Diffuse alveolar hemorrhage (DAH), a subset of IPS, generally develops at the time of neutrophil recovery in the early post-HCT period in the immediate post-HCT period and is characterized by progressive shortness of breath, cough, and hypoxemia with or without fever (Afessa et al. 2001 ; Robbins et al. 1989 ; Lewis et al. 2000 ; Metcalf et al. 1994 ) . Classically, DAH is defi ned by the demonstration of progressively bloodier aliquots of BAL fl uid on successive saline lavages, but frank hemoptysis is rare (Robbins et al. 1989 ). Mortality from DAH may be as high as 75 % despite aggressive treatment with systemic corticosteroids, with death usually occurring within weeks of diagnosis (Lewis et al. 2000 ) . A small case series has suggested that high dose solumehol (1 gm/day) could be an effective treatment of DAH (Chao et al. 1991 ) . A retrospective study has suggested that the addition of aminocaproic acid to high dose corticosteroids could be of benefi t in the treatment of DAH (Wanko et al. 2006 ) . Some patients with DAH can have microorganisms isolated from blood, BAL fl uid, or tracheal aspirate within 1 week of alveolar hemorrhage. Majhail and colleagues compared patients with DAH and infection-associated alveolar hemorrhage who presented with similar clinical and radiographic fi ndings in the setting of progressively bloodier BAL fl uid following allogeneic HCT (Majhail et al. 2006 ). Alveolar hemorrhage from either infectious or noninfectious causes has extremely poor outcome following therapy with conventional agents, including steroids (Majhail et al. 2006 ). Peri-engraftment respiratory distress syndrome (PERDS) also falls within the defi nition of IPS (Afessa et al. 2001 ) . PERDS is characterized by fever, dyspnea, and hypoxemia that, by defi nition, occurs within 5-7 days of neutrophil engraftment (Capizzi et al. 2001 ; Wilczynski et al. 1998 ; Bhalla et al. 2000 ) . Although PERDS after autologous HCT appears similar to IPS after allogeneic HCT with respect to clinical presentation and time of onset, PERDS/IPS following autologous transplantation differs sharply from PERDS/IPS in the allogeneic setting, with signifi cantly improved outcomes in the autologous setting (Kantrow et al. 1997 ; Yanik et al. 2002 ; Cahill et al. 1996 ; Capizzi et al. 2001 ) . Potential etiologies and risk factors for IPS include direct toxicity from HCT conditioning regimen, occult pulmonary infections, and immunologic factors related to acute GVHD Weiner et al. 1989 ; Kantrow et al. 1997 ; Atkinson et al. 1991 ; Della Volpe et al. 2002 ; Crawford and Hackman 1993 ; Sakaguchi et al. 2012 ) . In particular, the cumulative incidence of IPS is signifi cantly less following the use of reduced intensity conditioning regimen when compared to conventional, myelo-ablative regimen (Fukuda et al. 2003 ) . Acute GVHD often precedes IPS, suggesting a possible causal relationship between the two disorders (Crawford and Hackman 1993 ; Bortin et al. 1989 ; Beschorner et al. 1978 ; Weiner et al. 1986 ; Kantrow et al. 1997 ; Afessa et al. 2001 ) . However, although IPS may correlate with the presence of acute GVHD, it does not necessarily correlate with the severity of GVHD, consistent with clinical reports of IPS in allogeneic HCT recipients whose signs and symptoms of GVHD were mild or absent (Yanik et al. 2002 ; Schultz et al. 1994 ; Curtis et al. 1995 ; Clark et al. 1987 ; Holland et al. 1988 ; Schwarer et al. 1992 ) . Historically, the lung has not been recognized as a classic target organ for GVHD, and the specifi c role of alloreactive donor T-lymphocytes in the pathogenesis of IPS is under considerable debate. Epithelial apoptosis is usually attributed to T-cell-mediated injury and is considered pathognomonic for acute GVHD. Although identifi ed in the lungs of many patients with IPS (Yousem 1995 ; Beschorner et al. 1978 ) , epithelial apoptosis has not been consistently observed in allogeneic HCT recipients with lung dysfunction. Based upon murine models, the pathogenesis of IPS appears to be a complex interplay between soluble infl ammatory mediators (Th1 cytokines, lipopolysaccharide (LPS), infl ammatory chemokines), donor-derived effector T cells, accessory cells (myeloid, pulmonary macrophages), and resident epithelial and endothelial cells. Signifi cant increases in the total number of lymphocytes, macrophages, and neutrophils in the bronchoalveolar space (Cooke et al. 1996 ) , increased vascular permeability, plus elevated levels of TNFα and infl ammatory cytokines have been noted in the lung tissue and BAL fl uid in both murine models and from clinical samples from patients with IPS (Clark et al. 1998 ; Shankar and Cohen 2001 ; Cooke et al. 1996 Cooke et al. , 2000b Piguet et al. 1989a ) . A direct role for TNFα in the development of IPS has been established using strategies that either neutralize its effects (Piguet et al. 1987 ; Cooke et al. 2000b ) or use TNFα-defi cient mice as HCT donors (Cooke et al. 2000a ; Hildebrandt et al. 2004 ). Administration of rhTNFR-Fc, a soluble, dimeric, TNF-binding protein at the time of endotoxin challenge in mice, effectively prevents IPSassociated lung injury in this setting (Cooke et al. 2000b ) . Studies using genetically altered mice have shown that IPS is dependent upon donorderived, rather than host-derived, TNFα. While TNFα from both donor accessory cells (macrophage/monocytes) and T cells signifi cantly contributes to lung injury, the T-cell component (of TNFα) predominates . TNFα likely contributes to the development of IPS through both direct and indirect mechanisms. In addition to being directly cytotoxic, TNFα increases expression of infl ammatory chemokines ) and major histocompatibility complex (MHC) antigens, modulates leukocyte migration, and facilitates cell-mediated cytotoxicity, including endothelial cell injury, a common feature of IPS (Gerbitz et al. 2004 ) . Strategies that neutralize TNFα in experimental models do not completely abrogate lung injury (Piguet et al. 1987 (Piguet et al. , 1989b Cooke et al. 2000b ; Clark et al. 2000 ; Hildebrandt et al. 2004 ) , suggesting that other infl ammatory and cellular mechanisms besides TNFα may also contribute to the development of IPS. For example, IL-1β, nitric oxide, and reactive oxygen species have also been implicated in the development of lung injury after HCT, particularly in the setting of myelo-ablative conditioning (Haddad et al. 1999 ; Panoskaltsis-Mortari et al. 1997 ; Qureshi et al. 2004 ). An analysis of plasma and BAL fl uid protein profi les in patients with IPS showed that in addition to increases in the levels of TNFα and its soluble receptors (TNFR1), signifi cant elevations in other Th1 cytokines (γ-interferon, IL-6) and proteins involved in the LPS cascade (sCD14, LBP) along with several infl ammatory chemokines (IL-8, MCP-1, MIG) that regulate leukocyte recruitment to sites of infl ammation were also evident (Yanik et al. 2008b ) . Treatment options for IPS have historically combined supportive care measures, including supplemental oxygen support, diuretics, broad-spectrum antimicrobial agents, and intravenous corticosteroids (Kantrow et al. 1997 ; Yanik et al. 2002 Yanik et al. , 2008b Tizon et al. 2012 ). High-dose corticosteroid therapy (>2 mg/kg/day of methylprednisolone equivalent) has not been shown to improve outcome when compared to lower doses of corticosteroids (≤2 mg/kg/day) (Fukuda et al. 2003 ) . More recently, the role for TNF inhibition in the management of IPS has been under investigation. A pilot study from the University of Michigan examined the use of a soluble TNF-binding agent, etanercept, in the treatment of patients who met the diagnostic criteria for IPS. A 4-week course of therapy was given, with a strict defi nition used to defi ne response (complete cessation of all oxygen support within 28 days of therapy onset). Responses were noted in ten (67 %) subjects, with survival 73 % within the therapy period (Fukuda et al. 2003 ; Yanik et al. 2008b ) . A retrospective review of 39 patients treated with either corticosteroids alone ( n = 22) versus corticosteroids plus etanercept ( n = 17) similarly noted high response rates in the etanercept arm. Overall survival was signifi cantly higher in those patients treated with corticosteroids plus etanercept, both at 28 days (88.2 % vs. 36.4 %, <0.001) and 2 years (18 % vs. 9.1 %, p = 0.003) following onset of IPS (Tizon et al. 2012 ) . Advances in supportive care, including the early institution of continuous veno-venous hemofi ltration, may provide additional help in improving survival, but prospective studies addressing the treatment of IPS with clinical trials are in progress. Based upon these encouraging results, larger phase II (pediatric) and phase III (adult) trials have recently been completed within the Bone Marrow Transplant Clinical Trials Network (phase III) and the Children's Oncology Group (phase II). Bronchiolitis obliterans syndrome was initially described in the 1980s as a form of chronic lung injury following allogeneic transplant and remains one of the most perplexing posttransplant conditions to manage (Holland et al. 1988 ; Crawford et al. 1995 ) . The clinical course is highly variable, ranging from a gradual decline in lung function over years to a rapid deterioration over several months. The incidence of BOS has varied from 2 to 25 % following allogeneic HCT, the wide range likely refl ecting the nonuniform diagnostic criteria used to defi ne the condition (Afessa et al. 2001 ; Williams et al. 2009 ). The disorder is associated with airfl ow obstruction on pulmonary function testing (PFT) with declines in forced expiratory volume in 1 s (FEV1) and FEV1/forced vital capacity (FVC) ratio required for diagnostic purposes. In early stages, BOS is characterized by small airway infl ammation with lymphocytic bronchitis, ultimately progressing to fi brinous obliteration of bronchiolar lumen (Schwarer et al. 1992 ; Urbanski et al. 1987 ; Cooke and Yanik 2009 ). Respiratory symptoms include cough, dyspnea, and wheezing, but many patients remain asymptomatic despite showing signs of moderate to severe airway obstruction on PFTs (Clark et al. 1987 ; Holland et al. 1988 ). Chest radiographs are most often normal except for signs of hyperinfl ation (Curtis et al. 1995 ; Holland et al. 1988 ; Schwarer et al. 1992 ) . Likewise, chest CT fi nd-ings range from normal early in the course of disease to extensive peribronchial infl ammation and bronchiectasis with signifi cant air trapping and diffuse parenchymal hypoattenuation at later time points (Schultz et al. 1994 ; Ooi et al. 1998 ) . One study has demonstrated that on high resolution CT scanning, BOS is characterized by central airway dilation, the degree of which correlates with decrement in lung function, and is distinct from the central airway narrowing observed with emphysema or asthma (Gazourian et al. 2013 ). The clinical course of BOS varies from mild to severe with necrotizing bronchiolitis and a rapid decline in respiratory function (Holland et al. 1988 ; Schultz et al. 1994 ; Sullivan et al. 1992 ; Sanchez et al. 1997 ; Curtis et al. 1995 ; Clark et al. 1989 ) . In 2005, a NIH Consensus statement on the diagnosis and staging of chronic GVHD included strict diagnostic criteria for BOS, with subsequent proposed modifi cations for improved identifi cation of BOS patients (Williams et al. 2009 ; Filipovich et al. 2005 ) (Table 5 .2 ). Studies published prior to the 2005 publication used various defi nitions of disease and response to therapy, making it diffi cult to translate previous results in the current era. The Fred Hutchinson Cancer Research Center recently utilized the NIH criteria to identify the incidence, risk factors, and mortality from BOS following allo- HCT (Au et al. 2011 ). The overall incidence of BOS was 5.5 % and as high as 14 % in patients with chronic GVHD. The median time to diagnosis was 439 days post-HCT, with chronic GVHD present in 100 % of patients identifi ed with BOS. Lower baseline FEV1 (<80 %) and circulating IgG levels were predictive of BOS onset. Previously reported risk factors for BOS, including busulfan-based regimen, peripheral stem cells as the donor source, methotrexate for GVHD prophylaxis, viral pneumonitis post-HCT, HLA mismatch, disease status, and the use of a myelo-ablative regimen, were not predictive of BOS in this report (Holland et al. 1988 ; Schultz et al. 1994 ; Clark et al. 1987 Clark et al. , 1989 Chien et al. 2003 Chien et al. , 2005 . Unfortunately, whereas risk factors for BOS have been identifi ed, no clear predictors of outcome have been reported. Therapy for BOS remains challenging, with no recognized standard therapy. Once established, the prognosis of BOS is very poor, with 5-year survival rates of 15 % (Chien et al. 2010 ) . Even answers to seemingly basic questions have yet to be determined. At what point should therapy be started? Are BAL, transbronchial, or surgical lung biopsies required prior to starting treatment? How should response be defi ned? A European GVHD consensus conference (2009) summarized diagnostic criteria and treatment options for pulmonary manifesta-tions of chronic GVHD, with a particular focus on BOS (Hildebrandt et al. 2011 ) . PFTs were recommended pre-HCT, every 3 months for the fi rst 2 years posttransplant, and every 6 months thereafter. When obstructive changes are noted on PFTs, then high-resolution computed tomography (HRCT) with inspiratory and expiratory images is recommended to assess for radiographic signs of BOS, including air trapping, bronchial wall thickening, and bronchiectasis ( Fig. 5.2 ) . The degree of obstructive changes (decline in FEV1) that would warrant a HRCT was not specifi ed, though at many centers a 10 % decline in FEV1 would typically initiate a HRCT, especially if the FEV1 was <80 % predicted. Systemic and topical (inhaled) corticosteroids, mTOR inhibitors, extracorporeal photo pheresis (ECP), imatinib, azithromycin, montelukast, and combination topical corticosteroid-bronchodilators have all been utilized with varying degrees of success (Hildebrandt et al. 2011 ) . Few BOS treatment options have been based upon prospective clinical trials (Ratjen et al. 2005 ; Khalid et al. 2005 ; Couriel et al. 2006 ; Yanik et al. 2012 ) . Systemic and topical corticosteroids have become commonplace in managing BOS, supported by small case reports and observational studies (Ratjen et al. 2005 ; Ishii et al. 2000 ; Bergeron et al. 2007 ; Bashoura et al. 2008 ) . Three retrospective studies support the use of inhaled corticosteroids Inspiratory Expiratory (Bergeron et al. 2007 ; Bashoura et al. 2008 ; Norman et al. 2011 ) . The combination of systemic plus inhaled corticosteroids has been examined in a few studies. In one trial, repetitive courses of oral methylprednisolone (10 mg/kg/ day) plus inhaled budesonide led to disease stabilization in 7 of 9 patients (Ratjen et al. 2005 ) . The combination of an inhaled steroid plus long-acting bronchodilator (budesonide/formoterol) was reported in 13 patients with BOS, with clinical improvement noted in all 13 patients; responses were seen at a mean 2.3 months following onset of therapy (Bergeron et al. 2007 ). In another case series, the use of inhaled fl uticasone, azithromycin, and montelukast (FAM) therapy was useful in "sparing" systemic corticosteroid usage in eight patients with BOS (Norman et al. 2011 ). The Chronic GVHD Consortium has begun enrolling patients into a clinical trial investigating the use of FAM therapy for newly diagnosed BOS (NCT01307462). The use of macrolide antibiotics (azithromycin) for frontline therapy of BOS is widespread in the transplant community, though based upon a single report of eight HCT patients receiving a 12-week course of therapy (Khalid et al. 2005 ). Subjects did not undergo pre-therapy BAL, thus questioning whether subsequent responses were secondary to anti-infl ammatory or antimicrobial effects of the agent. There are no published reports justifying the use of azithromycin for BOS prevention. In an observational study of 81 patients with BOS following lung allografts, 24 of 81 (30 %) experienced an improvement in FEV1 after 6 months of azithromycin therapy (Gottlieb et al. 2008 ) . The presence of neutrophilia in pretherapy BAL was not only a positive predictor for subsequent response but also suggested a mechanistic role for azithromycin in this clinical setting (Gottlieb et al. 2008 ) . The published reports on the benefi ts of ECP for BOS following HCT are even less compelling (Couriel et al. 2006 ; Lucid et al. 2011 ; Child et al. 1999 ) , with only one focusing on patients with BOS post-HCT (Lucid et al. 2011 ) . Stabilization in FEV1 was reported in six of nine patients in this retrospective report, comparing FEV1 values prior to and during ECP therapy (Lucid et al. 2011 ) . A phase II clinical trial using etanercept for the treatment of chronic lung injury post-HCT was reported in 2012 (Yanik et al. 2012 ) . Etanercept was administered to 31 patients with either BOS ( n = 22) or restrictive lung disease ( n = 9), with NIH Consensus Criteria used to defi ne the cohort of patients with BOS. For subjects with BOS, response was defi ned as a ≥10 % improvement in FEV1 within 4 weeks of therapy completion. Responses were noted in 7 of 22 (32 %) patients with BOS, with no differences in response based upon the severity of pulmonary disease at study onset. Therapy was well tolerated, with few infectious complications. Estimated 5-year OS was 90 % (95 % CI, 73-100 %) for patients who responded to therapy (Yanik et al. 2012 ) . The study deserves particular notice for its use of strict eligibility and response criteria. All patients underwent pre-and post-therapy BAL, HRCT, plasma biomarker analysis, and PFTs, with additional PFTs performed monthly during therapy. No changes in adjuvant immune-suppressive therapy were allowed within the initial 28 days of therapy (Yanik et al. 2012 ) . The lack of defi ned response criteria greatly limits our ability to compare therapy strategies for BOS. Does a 10 % improvement in FEV1, as used in the etanercept BOS trial, even equate to improved performance? Are FEV1 and FEV1/ FVC the best measures of airway obstruction (and response), or would changes in FEV1/slow vital capacity (SVC) serve as a better indicator of response in small airway disease (Au et al. 2011 )? Should quality of life (QOL) assessments be included in the response analysis? The etanercept trial was unique in that validated quality of life (QOL) instruments were additionally used to assess patient performance during therapy. However, no difference in QOL outcome measures (pre-therapy vs. post-therapy) was noted in subjects that responded or did not respond to therapy (Yanik, unpublished observations) . The development of BOS likely involves an initial insult to lung parenchyma followed by an ongoing infl ammatory process involving immune effector cells and the resident cells of the pulmonary vascular endothelium and interstitium. Much of our knowledge regarding the pathogenesis of BOS is based upon observations made in lung allograft recipients and from data generated in murine tracheal transplant models. Strong Th1 immune responses have been noted in rat heterotopic lung allografts, the Th1 response present even after fi brosis and airway obliteration was complete (Boehler et al. 1999 ) . Several groups have shown enhanced expression of TNFα, IL-8, TGFβ, and IL-1β during lung allograft rejection (Belperio et al. 2002 ; Elssner et al. 2000 ; Fattal-German et al. 1998 ; El-Gamel et al. 1999 ) and additionally revealed critical roles for both RANTES and MCP-1 in the development of experimental BOS (Belperio et al. 2000 (Belperio et al. , 2001 . Ultimately, advances in the management of BOS will require improvements in our understanding of the basic pathophysiology of the disorder. A murine model for BOS has been reported, with peribronchiolar infl ammation and airway resistance in the mice mimicking the human model (Panoskaltsis-Mortari et al. 2007 ; Srinivasan et al. 2012 ) . The potential benefi ts of this murine model remain to be elucidated, in terms of improving our understanding of this enigmatic disorder and designing optimal treatment strategies. Bronchiolitis obliterans organizing pneumonia (BOOP) was fi rst described in allogeneic HCT in the early 1990s, presenting as acute bilateral airspace disease within the fi rst 2-6 months posttransplant (Thirman et al. 1992 ; Mathew et al. 1994 ) (Fig. 5.3 ) . In contrast to BOS, in which bronchiolar damage predominates, BOOP is primarily an alveolar disorder. The disorder is characterized by extensive infi ltration of granulation tissue within alveoli, with fi broblasts and a matrix of loose connective tissue deposits. The patho-physiology is poorly understood, though a strong association with acute and/or chronic GVHD (Freudenberger et al. 2003 ; Jinta et al. 2007 ), a possible link to HLA B35 (Yotsumoto et al. 2007 ) , and decreased incidence following T-celldepleted HCT (Ditschkowski et al. 2007 ) are all supportive of an alloimmune mechanism. To avoid confusion with BOS, the disorder has been renamed cryptogenic organizing pneumonia (COP) in the pulmonary community. Though consensus diagnostic criteria are lacking, the incidence of BOOP is estimated at 1-2 %, based upon single institution reports (Freudenberger et al. 2003 ; Jinta et al. 2007 ) . In contrast to IPS and BOS, BOOP typically presents with fever, dyspnea, and a nonproductive cough, with PFTs revealing a restrictive defect (FVC <80 %, FEV1/FVC ≥80 %) (Table 5 .3 ). HRCT reveals peripheral air space consolidation, with ground-glass and nodular opacities commonly identifi ed (Lee et al. 1994 ; Pipavath et al. 2012 ) . Given the clinical presentation and radiographic fi ndings, infectious etiologies must be ruled out in all patients. Despite the collective support for the diagnosis of BOOP based upon clinical fi ndings and radiographic presentation, There is no standard treatment for BOOP, and no clinical trials are currently listed on clinicaltrials . gov . Based on limited retrospective reviews, systemic corticosteroids (1.0 mg/kg/ day) would be considered the treatment of choice, with prolonged treatment courses recommended secondary to high rates of recurrence during taper (Thirman et al. 1992 ; Mathew et al. 1994 ; Freudenberger et al. 2003 ; Jinta et al. 2007 ). Reported response rates are 50-60 %, with overall survival approximately 50-70 % (Freudenberger et al. 2003 ; Jinta et al. 2007 ). Our overall understanding of BOOP is limited, with no consensus diagnostic criteria, a lack of prospective trials and minimal understanding of the underlying pathophysiology. All three disorders IPS, BOS, and BOOP are postulated to be caused by alloimmune injury. However, why such alloreactivity would selectively target the interstitium and broncho-alveoli in IPS, bronchiolar structures in BOS, and the alveoli in BOOP remains poorly understood. Hepatic Veno-occlusive Disease/Sinusoidal Obstruction Syndrome Hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), is a potentially life-threatening complication after HCT. Hepatic VOD/SOS affects both adult and pediatric populations and both allogeneic and autologous graft recipients, with a higher incidence in the allogeneic setting Carreras 2012 ) . The onset of VOD/SOS is well described within the fi rst 30 days after HCT , though later occurrences have been reported. It is characterized by clinical features including hepatomegaly, jaundice, weight gain, and ascites Coppell et al. 2010 ) . VOD/SOS is reported to occur in 8-14 % of patients following HCT ), although incidence rates may be as high as 60 % in higher-risk patients (such as those with underlying liver disease and certain specifi c drug exposures, including gemtuzumab ozogamicin and sirolimus), and depending upon the diagnostic criteria used Coppell et al. 2010 ) . Severe VOD/SOS is typically associated with multiorgan failure (MOF) and high mortality rates (>80 %) Coppell et al. 2010 ) . Even among patients with moderate VOD/ SOS, the mortality rate is still estimated at approximately 20 % (McDonald et al. 1984 ). VOD/SOS is thought to be triggered by activation of and damage to the sinusoidal endothelial cells (SECs) in zone 3 of the hepatic acinus due to conditioning regimen-mediated injury (Guglielmelli et al. 2012 ) . As shown in Figure 5 .4 , exposure of SEC's to conditioning radiation or toxic metabo-lites of chemotherapy leads to SEC injury and activation. Activated SECs express cytokines (e.g., TNFα and IL-1β) and adhesion molecules (e.g., ICAM-1 and VCAM-1) resulting in activation of proinfl ammatory pathways that further damage the endothelium (Coppell et al. 2003 ) . This leads to the loss of endothelial wall fenestrae and formation of gaps between SECs (Panel B) (Carreras 2012 ) . Consequently, red blood cells, leukocytes, and cellular debris extravasate into the space of Disse, causing progressive extraluminal compressive narrowing of the sinusoids (Carreras 2012 ; Coppell et al. 2003 ; Bearman 1995 ) and dissection of the endothelial cells, which could further embolize downstream and occlude the sinusoid (Panel C) (Carreras 2012 ). In addition, injury to the SECs of the sinusoids is also associated with a procoagulant and hypofi brinolytic state that contributes further to fi brin deposition, clot formation in situ, and narrowing of the sinusoids (Guglielmelli et al. 2012 ; Coppell et al. 2003 ; Bearman 1995 ) . Together, these effects reduce hepatic venous outfl ow, leading to post-sinusoidal hypertension, central venular occlusion, hepatic enlargement with capsular distension, and, in more severe cases, portal venous fl ow reversal and hepatorenal syndrome, leading to multiorgan failure (MOF) and death (Carreras 2012 ) (Fig. 5.4 ) . The diagnosis of VOD/SOS is made based on clinical criteria with two established systems, the Seattle criteria (Bearman 1995 ) and the Baltimore criteria Jones et al. 1987 ; Richardson et al. 1998 ). The Seattle criteria require at least two or more clinical features including jaundice, painful hepatomegaly or ascites, and/or unexplained weight gain within 30 days of transplantation (Bearman 1995 ; ). The Baltimore criteria specify an elevated bilirubin level of at least 2.0 mg/dL and two or more of the following characteristics: hepatomegaly, ascites, or at least 5 % weight gain by day +21 post-HCT, with the Baltimore criteria validated according to both histopathologic features as well as outcome (Bearman 1995 ; Jones et al. 1987 ) . VOD/SOS presents with a wide clinical spectrum and is conventionally divided into mild, moderate, and severe disease (McDonald et al. 1993 ) . Mild VOD/SOS is considered disease that meets diagnostic criteria, does not require specifi c treatment for fl uid excess or medication for hepatic pain, and has a self-limiting course. Moderate VOD/SOS reveals evidence of liver injury with need for active treatment for fl uid excess or medication for hepatic pain but usually resolves completely. Severe VOD/SOS is defi ned in association with MOF and severe hyperbilirubinemia with rapid weight gain and has very high mortality rate (DeLeve et al. 2009 ). Although several biomarkers of endothelial injury have been described in the literature, including plasminogen activator inhibitor type-1 (PAI-1) (Nurnberger et al. 1998 ; Salat et al. 1994 ) , no laboratory marker has been validated as a diagnostic marker of VOD/SOS. From retrospective analyses, the presence of multiorgan failure has emerged as the most useful marker for VOD/SOS severity to date. The Bearman model, developed in the 1990s, estimates the risk of developing severe VOD/SOS based on bilirubin level, percentage weight gain, and a designated time frame from HCT; this model has demonstrated some utility for predicting VOD/SOS severity. However, as the Bearman model was developed in a cohort of patients who developed VOD/SOS within 17 days of HCT after specifi c conditioning regimens, its general applicability to other conditioning regimens and later time frames post-HCT is limited Coppell et al. 2010 ; Bearman et al. 1993 ) . In this context, sensitive and specifi c biomarker assays are needed that could guide disease prognostication and management, with some candidate markers under study but none yet defi ned. (Richardson et al. 1998 ) . A number of The promising results observed with DF in VOD/SOS treatment trials have led to investigation of its use as prophylaxis for VOD/SOS following HCT. A number of prospective historically controlled trials have reported benefi ts with DF prophylaxis in pediatric patients at high risk of developing VOD/SOS (Cappelli et al. 2009 ; Corbacioglu et al. 2006 ; Qureshi et al. 2008 ). These studies are also supported by the recent prospective multicenter phase II/III study in Europe . In this trial, 360 children (<18 years) who were undergoing myelo-ablative HCT were randomized to receive either prophylactic DF from conditioning to 30 days post-HCT or no prophylaxis (as a control group). In an intent-to-treat analysis, there was a 40 % reduction in VOD/SOS by day 30 post-HCT in patients receiving prophylactic DF when compared with control (12 % vs. 20 %; p = 0.051). Of note, the mortality at 100 days was four times higher in patients who developed VOD/SOS compared to those without VOD/SOS (25 % vs. 6 %; p < 0.0001). Interestingly enough, the incidence of acute GVHD was also signifi cantly lower in the DF prophylaxis arm, an observation consistent with similar fi ndings in treatment studies ). Despite the promising results from clinical trials with DF as treatment and prevention of VOD/SOS, day 100 mortality from VOD/SOS remains unacceptably high. The importance of early intervention is key, with recent clinical observations indicating that delays in the initiation of VOD/SOS treatment are associated with worse outcomes (Richardson et al. 2011 ) . The role of DF in VOD/SOS management may, in fact, be optimized with its use in early disease or as prophylaxis. Additional prospective studies in VOD/SOS prevention are now planned in adult HCT populations and specifi c high-risk settings. Elevations of von Willebrand factor, thrombomodulin, E-selectin, and soluble ICAM-1 before and early after allogeneic transplantation may be useful in predicting VOD/SOS in patients receiving sirolimus (Cutler et al. 2010 ) as GVHD prophylaxis and could lead to preemptive treatment or prevention trials based on these and other biomarkers . Finally, additional therapies, such as low molecular weight heparin, N-acetyl cysteine, antithrombin III, and other novel antithrombotics may warrant further investigation in combination with DF Ho et al. 2008 Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients Upregulation of T-helper 1 cytokines and chemokine expression in post-transplant airway obliteration Radiation toxicity following busulfan/melphalan high dose chemotherapy in the euro-ewing-99-trial Temporal relationships between the major complications of bone marrow transplantation for leukemia Marrow engraftment and clincial manifestations of capillary leak syndrome Peri-engraftment respiratory distress syndrome during autologous hematopoietic stem cell transplantation Absence of VOD in paediatric thalassaemic HSCT recipients using defi brotide prophylaxis and intravenous Busulphan Early complications after HSCT The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade Corticosteroid therapy for diffuse alveolar hemorrhage in autologous bone marrow transplant recipients Airfl ow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graftversus-host disease Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD) Defi brotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study Risk factors for airfl ow obstruction in recipients of bone marrow transplants Obstructive lung disease after allogeneic marrow transplantation. Clinical presentation and course NHLBI workshop summary. Idiopathic pneumonia syndrome after bone marrow transplantation Lung injury induced by alloreactive Th1 cells is characterized by host-derived mononuclear cell infl ammation and activation of alveolar macrophages Idiopathic pneumonia after bone marrow transplantation: cytokine activation and lipopolysaccharide amplifi cation in the bronchoalveolar compartment Neutralization of tumor necrosis factor-alpha action delays but does not prevent lung injury induced by alloreactive T helper 1 cells Lung injury following hematopoietic stem cell transplantation An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin Hyporesponsiveness of donor cells to lipopolysaccharide stimulation reduces the severity of experimental idiopathic pneumonia syndrome: potential role for a gut-lung axis of infl ammation Tumor necrosis factor-alpha neutralization reduces lung injury after experimental allogeneic bone marrow transplantation Veno-occlusive disease: cytokines, genetics, and haemostasis Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defi brotide Defi brotide for prophylaxis of hepatic venoocclusive disease in paediatric haemopoietic stem-cell transplantation: an open-label Defi brotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation Extracorporeal photopheresis for acute and chronic graft-versus-host disease: does it work? Clinical course of idiopathic pneumonia after bone marrow transplantation Acute graft versus host disease and the risks for idiopathic pneumonia after marrow transplantation for severe aplastic anemia Abnormalities of pulmonary function tests after marrow transplantation predict nonrelapse mortality Chronic airfl ow obstruction in long-term survivors of allogeneic bone marrow transplantation Prediction of veno-occlusive disease using biomarkers of endothelial injury Revised defi nitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer / Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and infectious Diseases Mycoses Study Group (EORTC / MSG) Consensus Group Vascular disorders of the liver Lethal pulmonary complications signifi cantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors Respiratory syncytial virus pneumonitis in immunocompromised adults: clinical features and outcome Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fl uid from patients with bronchiolitis obliterans syndrome: proinfl ammatory role of bronchial epithelial cells Respiratory syncytial virus infection in immunocompromised adults Brief communication: fatal human metapneumovirus infection in stem-cell transplant recipients Expression and modulation of ICAM-1, TNF-alpha and RANTES in human alveolar macrophages from lung-transplant recipients in vitro National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation Gentium-Announces-Submission-Of-A-Marketing-Authorization-Application-For-Defi brotide-To-The A role for tumor necrosis factor-alpha-mediated endothelial apoptosis in the development of experimental idiopathic pneumonia syndrome Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: impact on coagulation profi le Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital Update on the use of defi brotide High levels of peroxynitrite are generated in the lungs of irradiated mice given cyclophosphamide and allogeneic T cells. A potential mechanism of injury after marrow transplantation An outbreak of respiratory syncytial virus in a bone marrow transplant center Successful treatment of an infant with veno-occlusive disease developed aft er allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1 Donor-derived TNF-alpha regulates pulmonary chemokine expression and the development of idiopathic pneumonia syndrome after allogeneic bone marrow transplantation Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD Hepatic venoocclusive disease after hematopoietic stem cell transplantation: update on defi brotide and other current investigational therapies Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-versus-host disease and low serum IgG Bronchoalveolar lavage in the diagnosis of pulmonary complications of bone marrow transplant patients Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients Improvement in bronchiolitis obliterans organizing pneumonia in a child after allogeneic bone marrow transplantation by a combination of oral prednisolone and low dose erythromycin Clinical features of allogeneic hematopoietic stem cell transplantation-associated organizing pneumonia Venoocclusive disease of the liver following bone marrow transplantation Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation Investigations into the role of anti-HLA class II antibodies in TRALI Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study Transfusion-related acute lung injury: report of a clinical look-back investigation TRALI: correlation of antigen-antibody and monocyte activation in donor-recipient pairs Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD) Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide following by autologous stem cell transplant Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): effi cacy of recombinant human tissue plasminogen activator (rt-PA) treatment Cryptogenic organizing pneumonia: CT fi ndings in 43 patients Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafi le analysis Extracorporeal photopheresis in patients with refractory bronchiolitis obliterans developing after allo-SCT Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes Prospective study of infectious complications in allogeneic hematopoietic stem cell transplant recipients Bronchiolitis obliterans organizing pneumonia (BOOP) in children after allogeneic bone marrow transplantation Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Corticosteroids as adjunctive therapy for diffuse alveolar hemorrhage associated with bone marrow transplantation azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications High-resolution computed tomography of bronchiolitis obliterans syndrome after bone marrow transplantation CMV antigenemia following bone marrow transplantation: risk factors and outcomes An offi cial American Thoracic Society Research Statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome The critical early proinfl ammatory events associated with idiopathic pneumonia syndrome in irradiated murine allogeneic recipients are due to donor T cell infusion and potentiated by cyclophosphamide A new murine model for bronchiolitis obliterans post-bone marrow transplant An offi cial American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-versus-host disease Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fi brosis Pneumopathies of the graft-versus-host reaction. Alveolitis associated with an increased level of tumor necrosis factor MRNA and chronic interstitial pneumonitis Organizing pneumonia in recipients of hematopoietic stem cell transplantation: CT features in 16 patients Role of fl exible bronchoscopy in immunocompromised patients with lung infi ltrates The lung as a critical organ in marrow transplantation The effects of bone marrow transplantation on pulmonary function in children Increased exhaled nitric oxide following autologous peripheral hematopoietic stem-cell transplantation: a potential marker of idiopathic pneumonia syndrome Defi brotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children High-dose corticosteroid therapy for bronchiolitis obliterans after bone marrow transplantation in children Measures to prevent transfusion related acute lung injury Cytomegalovirus infection and disease after bone marrow transplantation: epidemiology, prevention, and treatment Treatment of severe veno-occlusive disease with defi brotide: compassionate use results in response without signifi cant toxicity in a high-risk population Multi-institutional use of defi brotide in 88 patients aft er stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome Defi brotide (DF) in the treatment of severe hepatic veno-occlusive disease (VOD) with multi-organ failure (MOF) following stem cell transplantation (SCT): results of a phase 3 study utilizing a historical control Defi brotide for the treatment of severe hepatic venoocclusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dosefi nding trial Defi brotide (DF) in the treatment of hepatic veno-occlusive disease (VOD) in stem cell transplant (SCT) and non-SCT patients (Pts): early intervention improves outcome -updated results of a treatment IND expanded access protocol Drug safety evaluation of defi brotide Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients Incidence, clinical features, and risk factors of idiopathic pneumonia syndrome following hematopoietic stem cell transplantation in children Parameters of the fi brinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease Long term follow up of immunosuppressive treatment for obstructive airway disease after allogeneic bone marrow transplantation Obstructive lung disease in children after allogeneic bone marrow transplantation Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation A chronic pulmonary syndrome associated with graft-versus-host disease after allogeneic marrow transplantation Idiopathic pneumonia syndrome after bone marrow transplantation: the role of pre-transplant radiation conditioning and local cytokine dysregulation in promoting lung infl ammation and fi brosis Utility of early versus late fi beroptic bronchoscopy in the evaluation of new pulmonary infi ltrates following hematopoietic stem cell transplantation Fatal pulmonary fi brosis associated with BCNU: the relative role of platelet-derived growth factor-B, insulin-like growth factor I, transforming growth factor-beta1 and cyclooxygenase-2 Adenovirus infections in patients undergoing bone-marrow transplantation Cytomegalovirus pneumonitis presenting small nodular opacities Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans Late complications of allogeneic and autologous bone marrow transplantation Transfusionrelated acute lung injury (TRALI): current clinical and pathophysiologic considerations Bronchiolitis obliterans organizing pneumonia as a complication of allogeneic bone marrow transplantation High-dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allo-SCT Idiopathic small airways pathology in patients with graft-versus-host disease following allogeneic bone marrow transplantation Diffuse alveolar hemorrhage: retrospective review of clinical outcome in allogeneic transplant recipients treated with aminocaproic acid Interstitial pneumonitis after bone marrow transplantation Risk factors for interstitial pneumonitis following bone marrow transplantation for severe aplastic anemia Cryptogenic organizing pneumonia Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation Management of noninfectious lung injury following hematopoietic cell transplantation Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation Impact of broncho-alveolar lavage on the diagnosis and management of pulmonary complications post transplant The impact of soluble tumor necrosis factor receptor etanercept on the treatment of idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation Bronchiolitis obliterans organizing pneumonia after bone marrow transplantation: association with human leukocyte antigens The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients Recombinant tissue plasminogen activator (rt-PA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients We would like to thank Michelle Maglio, Sandy Klaus and Verica Saveski for their tremendous help and assistance in the preparation of this chapter.